Audit: QRS - Tai Chi for Health & Longevity

Audit conducted on 02/09/2026 06:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol cell, benefit, risk, contraindication, interaction, biomarker row and qualitative marker traces to a named ER passage (ER Therapeutic Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring Protocol & Defining Success, Practical Considerations, Conclusion).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER section carries an empty-state or hedged phrasing that the QRS surfaces; marker_10_target mirrors the ER’s “No established target; track the direction of change against the individual’s own baseline”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain their absolute framing; speculative risks stay in the speculative tier; “neither shown superior” matches the ER’s “Neither approach has been shown superior”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid Tai Chi” list, Key Interactions only from the ER’s interaction bullets; no Benefit-Modifying Factors or Risk-Modifying Factors content is promoted into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The only named program, “Moving for Better Balance”, appears in the ER Therapeutic Protocol for the same fact; no PMIDs, NCT identifiers, author names or years appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No investigator, institution or sponsor is named beyond what the ER carries.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, sceptical register, including carrying forward the ER’s conflict-of-interest caveat into at_a_glance.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and doses are paired with plain-language framing; no alarmism and no promotional language.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as findings and protocols observed in trials, not as instructions issued to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend”, “advise” or equivalent appears in the document’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol, Monitoring and Qualitative Assessment cells are descriptive noun phrases and values throughout.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are load-bearing decision gates (“New York Heart Association Class IV”, “aortic stenosis”, “25-hydroxyvitamin D”); no avoidable jargon is introduced.
2.8	Information is presented in a concise and very compact manner	🟢	ER sentences are reduced to phrases; sub-cells run one to two clauses; parenthetical glosses are stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for second-person forms; none present.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges rather than conventional disease cutoffs are given for every biomarker, and the opportunity-cost risk is carried at Medium tier.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	The 2 × 60 min weekly, 24-week supervised protocol is presented without softening the time commitment.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No “start small” or adherence-lowering framing; the full trial dose is the headline value.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	risks_medium elevates insufficient strength and peak-aerobic stimulus — an opportunity cost specific to adults already training — exactly as the ER frames it.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title carries “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register is used throughout; the plain-language wording in at_a_glance is mandated by item 7.4 for that region only.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All twelve fixed strings match the template byte-for-byte (lines 445, 491, 535, 570, 587, 627, 652, 656–658, 796 and the four tier labels).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	74 data-qrs-var spans present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 × label/value/sub, time_1–3 × label/value/sub, benefits × 4, stop_items, caution_items, risks × 4, marker_1–11 × name/target/why, monitoring_cadence, qualitative_item_1–7.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" are unchanged; a diff of the head/CSS block against the template shows no modification outside the metadata and title.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty; every benefit tier, risk tier, gate and monitoring row has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard evidence-based dose”, “Style selection”, “Conventional approach — therapeutic tai ji quan”) and all nine interaction labels reproduce the ER bold labels, with only the definitional glosses trimmed inside parentheses as item 9.5 permits.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is reworded or newly coined; every drug-example list inside a label is retained in full.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	A full-file Unicode scan returns no emoji code points; tiering is conveyed by the <strong> labels and the CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the ER’s minimum informative form — glosses stripped, sentences reduced to phrases, mechanisms and citations dropped — with no extraneous content that could be cut without violating the completeness requirements of items 8.2, 9.2, 14.2 and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens on line 2 immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding label text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are echoed by any visible element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All eight scalar values are unquoted and trimmed; duration: "00:04" is quoted because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: tai_chi_2026-0902-0141_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0902-0618.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number, with no context-window or tier qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: tai_chi_2026-0902-0141_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Tai Chi for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Tai Chi for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/02/2026, the MM/DD/YYYY form of 2026-0902-0618.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER’s “Also known as:” line is correctly omitted.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs — the replicated benefit set, the conflict-of-interest caveat, what tai chi does not deliver, and the time cost.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Benefit list, “groups with a stake in the result”, “builds no muscle or peak fitness” and “two supervised hours weekly for several months” each map to a separate Conclusion sentence.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “thinking and mood” for cognition and affect, “peak fitness” for peak aerobic capacity; no acronym or clinical-register term appears.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year or sample size is named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Directional wording only (“fewer falls”, “lower blood pressure”); no numeric effect estimate or interval.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the ER’s “Populations who should avoid Tai Chi:” list inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Seven ER bullets map one-to-one onto seven <li> items with no additions or omissions.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 573–582: seven discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Definitional glosses (“heart-related chest pain…”, “a narrowed main heart valve”, “a swollen, fluid-filled knee joint”) are stripped; no dash-trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 6 weeks”, “within 4 weeks”, “New York Heart Association Class IV”, “above 180/110 mmHg” and “within 6 weeks of surgery” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items come from the ER’s interaction bullets in that section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interaction bullets are present; none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 590–617: nine discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to its label plus a one-to-four-word consequence; the ER’s mitigation sentences are dropped. The single em-dash occurs inside the ER’s own bold label (“Other interventions — resistance and high-intensity training”), not as a trailing clause.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All 21 named example agents are retained across the eight parenthesised labels; only the definitional prefixes (“oral medications that make the pancreas release more insulin —”, “sleep-inducing medications —”, “medications that slow blood clotting —”) are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such interactions and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets on dose, style selection and the conventional/integrative approaches.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose (2 × 60 min weekly, 24 weeks), style choice (Yang 24-posture) and programme variant (Moving for Better Balance vs. traditional whole form) are the three bullets that determine what a practitioner actually does.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells carry substantive ER-derived content; no placeholder remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Balance, the pain/sleep/blood-pressure cluster and cognition are exactly the domains the ER Practical Considerations time-to-effect bullet names.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Balance leads, matching the ER’s strongest and most replicated signal (falls and balance), followed by the mid-tier pain/sleep/blood-pressure cluster, then the duration-dependent cognitive effect.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three or more distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells carry ER-derived content, including the 24-vs-12-week fibromyalgia comparison from the ER Therapeutic Protocol.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eighteen entries map to the ER Expected Benefits sub-headings in the same tier and the same order.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated (lines 537, 546, 552, 558).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER sub-heading reduced to a bare outcome phrase; no magnitude, confidence interval or mechanism is carried.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit tier; the ER’s “⚠️ Conflicted” markers and magnitude paragraphs are all dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry ER content, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six entries map to the ER Potential Risks & Side Effects sub-headings in the same tier and order.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated (lines 629, 632, 638, 641).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk-difference figures, confidence intervals and the “the disease, not the practice” reasoning from the ER are all omitted; entries are bare outcome phrases.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk tier; the ER’s “⚠️ Conflicted” marker on advanced heart failure is dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry ER content, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets and rationales all derive from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER table rows are present in order: blood pressure, waist circumference, fasting glucose, glycated hemoglobin, hs-CRP, lipid panel, 25-hydroxyvitamin D, bone mineral density T-score, resting heart rate, heart-rate variability, Timed Up and Go. Targets match the ER’s optimal functional ranges exactly.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 787–790 reproduce the ER’s cadence paragraph: functional tests at 4 and 12 weeks, blood pressure monthly, blood chemistry at 3 months then every 6–12 months, bone density every 2 years.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items come from the ER’s “Qualitative and functional markers worth tracking alongside the laboratory values” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER bullets are present: single-leg stance with eyes closed, confidence in unstable tasks, near-falls and stumbles, sleep onset latency and awakenings, unprompted execution of the full form, morning joint stiffness, perceived stress and emotional reactivity.

Issues 02/09/2026 06:32

Pass rate 100.00%. No issues found.

Issues 02/09/2026 06:24

1. 4.5 — Sheet overflows one A4 page: The Monitoring table (11 rows, lines 665-831) and the Key Interactions gate (9 items, lines 594-630) alone consume roughly 80% of the printable A4 height, and together with the header, At-A-Glance, Protocol panel, Benefits, Risks and the 7-item Qualitative Assessment the sheet runs to roughly two pages; no per-section condensation was applied.

Fixes 02/09/2026 06:24

1. 4.5 — Monitoring rationales condensed: Rewrote all eleven marker_#_why cells and marker_6_target / marker_10_target as single short phrases (e.g. “The best-evidenced laboratory effect of tai chi” → “Best-evidenced laboratory effect”), cutting the Monitoring table from roughly 23 wrapped lines to 14 without dropping any of the ER’s eleven biomarkers.
2. 4.5 — Key Interactions tightened: Trimmed the consequence clause on each of the nine interaction items to its key fact (e.g. “hypoglycemia at unchanged doses” → “hypoglycemia”, “a minor in-class fall becomes a bleeding event” → “bleeding on a fall”), while keeping every ER bold label and example drug list intact.
3. 4.5 — Qualitative Assessment shortened: Reduced all seven qualitative markers to one rendered line each (e.g. “Number of near-falls and stumbles per month, which changes before the fall rate does” → “Near-falls and stumbles per month”).
4. 4.5 — Protocol and Time-to-effect subtexts condensed: Shortened the three action_#_sub and three time_#_sub cells (e.g. “At two sessions weekly, the earliest point at which trials detect change.” → “At two sessions weekly; earliest detected change.”), saving three rendered lines in the protocol panel.
5. 4.5 — Benefits, Risks and At-A-Glance trimmed: Removed redundant wording from benefits_high (“Reduced rate of falls” → “Reduced falls”, “improved global cognitive function” → “improved global cognition”), risks_speculative and at_a_glance (“Cost is time: about two supervised hours” → “Cost is about two supervised hours”), which also brought the At-A-Glance to 53 words.
6. 4.5 — Monitoring cadence compacted: Shortened the cadence line to “blood chemistry at 3 months, then every 6–12 months” while preserving every interval the ER states.